F M Investments LLC Purchases Shares of 42,004 Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)

F M Investments LLC bought a new stake in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 42,004 shares of the biopharmaceutical company's stock, valued at approximately $1,767,000.

Other large investors have also recently bought and sold shares of the company. Vanguard Group Inc. boosted its position in shares of Ultragenyx Pharmaceutical by 0.9% during the 4th quarter. Vanguard Group Inc. now owns 10,034,862 shares of the biopharmaceutical company's stock worth $422,167,000 after acquiring an additional 89,389 shares in the last quarter. Invesco Ltd. lifted its stake in Ultragenyx Pharmaceutical by 1.5% during the fourth quarter. Invesco Ltd. now owns 1,699,756 shares of the biopharmaceutical company's stock worth $71,509,000 after purchasing an additional 25,487 shares during the last quarter. Alliancebernstein L.P. boosted its holdings in Ultragenyx Pharmaceutical by 5.3% in the fourth quarter. Alliancebernstein L.P. now owns 1,627,932 shares of the biopharmaceutical company's stock valued at $68,487,000 after purchasing an additional 81,667 shares in the last quarter. Geode Capital Management LLC boosted its holdings in Ultragenyx Pharmaceutical by 4.4% in the third quarter. Geode Capital Management LLC now owns 1,571,081 shares of the biopharmaceutical company's stock valued at $87,296,000 after purchasing an additional 65,623 shares in the last quarter. Finally, Pictet Asset Management Holding SA increased its stake in Ultragenyx Pharmaceutical by 125.5% in the fourth quarter. Pictet Asset Management Holding SA now owns 1,173,638 shares of the biopharmaceutical company's stock valued at $49,375,000 after purchasing an additional 653,088 shares during the last quarter. Hedge funds and other institutional investors own 97.67% of the company's stock.

Remove Ads

Insider Activity at Ultragenyx Pharmaceutical

In other news, CEO Emil D. Kakkis sold 73,434 shares of the business's stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $42.10, for a total transaction of $3,091,571.40. Following the sale, the chief executive officer now owns 641,731 shares of the company's stock, valued at $27,016,875.10. The trade was a 10.27 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Thomas Richard Kassberg sold 6,028 shares of the firm's stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $42.10, for a total value of $253,778.80. Following the completion of the transaction, the executive vice president now directly owns 265,238 shares of the company's stock, valued at $11,166,519.80. The trade was a 2.22 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 124,643 shares of company stock worth $5,256,268 over the last three months. 5.80% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

RARE has been the subject of several research analyst reports. HC Wainwright restated a "buy" rating and issued a $95.00 target price on shares of Ultragenyx Pharmaceutical in a report on Friday, February 14th. Wedbush restated a "neutral" rating and issued a $48.00 price objective (up previously from $46.00) on shares of Ultragenyx Pharmaceutical in a research note on Monday, January 13th. Canaccord Genuity Group lifted their target price on Ultragenyx Pharmaceutical from $121.00 to $136.00 and gave the stock a "buy" rating in a research report on Tuesday, February 18th. Wells Fargo & Company upped their target price on Ultragenyx Pharmaceutical from $75.00 to $88.00 and gave the company an "overweight" rating in a research report on Friday, December 20th. Finally, JPMorgan Chase & Co. lifted their price target on Ultragenyx Pharmaceutical from $104.00 to $117.00 and gave the stock an "overweight" rating in a research report on Thursday, March 27th. One analyst has rated the stock with a hold rating and thirteen have given a buy rating to the stock. According to data from MarketBeat.com, Ultragenyx Pharmaceutical currently has an average rating of "Moderate Buy" and an average price target of $92.79.

Ultragenyx Pharmaceutical Stock Up 1.2 %

NASDAQ:RARE traded up $0.42 during midday trading on Tuesday, reaching $35.34. The stock had a trading volume of 852,305 shares, compared to its average volume of 809,369. The stock has a market cap of $3.32 billion, a P/E ratio of -5.57 and a beta of 0.61. The firm has a fifty day simple moving average of $39.17 and a two-hundred day simple moving average of $44.67. Ultragenyx Pharmaceutical Inc. has a 12-month low of $29.59 and a 12-month high of $60.37.

Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) last issued its earnings results on Thursday, February 13th. The biopharmaceutical company reported ($1.39) earnings per share for the quarter, missing the consensus estimate of ($1.32) by ($0.07). Ultragenyx Pharmaceutical had a negative net margin of 101.60% and a negative return on equity of 193.80%. The firm had revenue of $164.88 million during the quarter, compared to analysts' expectations of $163.23 million. On average, sell-side analysts anticipate that Ultragenyx Pharmaceutical Inc. will post -5.18 earnings per share for the current fiscal year.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.